drugset / Trial / NCT01346163

Add On Treatment for Cognitive Deficits in Schizophrenia

NCT01346163

Phase 1 Completed 16 enrolled University of Pennsylvania Pfizer · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of brain function. Data from this study will assist with the evaluation of the utility of functional magnetic resonance imaging, arterial spin labeling (ASL), and electrophysiologic measures in the detection of early signals of the effectiveness of medications developed to target cognitive impairment in schizophrenia. Safety and tolerability of PF-03654746 in this population will be also be evaluated.

Timeline

Start
2009-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator PF-03654746 Small molecule 0.5 mg
Comparator PF-03654746 Small molecule 1 mg

Indications